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ABSTRACT 
PRASHANT NAIR: Diagnosis: The buck starts here. The role of diagnosis in three areas 
of modern medicine 
(Under the direction of Tom Linden, Jan Yopp and Nortin Hadler) 
 
This thesis examines the role of diagnosis—traditional and molecular—in three areas of 
medicine: personalized cancer treatment, treatment of infectious diseases and treatment 
of controversial disorders lacking unambiguous physiological bases. The thesis uses a 
mix of statistics, expert interviews and patient anecdotes to address in the form of three 
feature stories three aspects pertinent to the role of diagnosis in modern medicine. The 
first story addresses the challenges to developing diagnostic markers for truly 
personalized cancer therapy. The second story features a recent advance in molecular 
diagnostics that has transformed the treatment of infectious diseases, especially hitherto-
unknown viral infections. The third story illustrates the plight of patients suffering from 
disorders whose very existence is controversial and for which doctors are unable to 
provide clear-cut diagnoses. 
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CHAPTER I 
INTRODUCTION 
The past decade of innovation in molecular biology has ushered in a new era of 
medicine. Personalized medicine, or the approach of fashioning treatments and 
prevention strategies for individuals and their diseases, is slowly changing the treatment 
of a range of disorders. Dr. Francis Collins, the former head of the Human Genome 
Project, defined personalized medicine as “using information about a person’s genetic 
makeup to tailor strategies for the detection, treatment or prevention of disease.” While 
this new movement in medicine has been afoot, advance is glacial, largely because of the 
enormous biological variability among individuals. To be successful, personalized 
medicine depends on an array of scientific disciplines and on collaboration between basic 
researchers and clinicians. In large measure, personalized medicine hinges on accurate 
diagnosis. Information about a specific individual or groups of individuals who share 
similar genetic or physiological characteristics helps doctors tailor treatment to groups of 
patients. Characterizing the patient’s ailment as comprehensively as the existing 
technology allows is the first step in developing designer drugs for personalized therapy 
and elevates diagnosis to a central role in personalized medicine. Indeed, physicians 
practicing personalized medicine must consider the corollary question that tries to define 
individual variability: Is one person’s heart attack or prostate cancer biologically 
different from another’s for a reason not based entirely on chance?
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To be sure, personalized medicine is in its infancy; the real deal—individualized 
therapy—is pie in the sky, largely because many diseases are minimally heritable and 
also because many diseases are controlled by multiple genetic factors. But the 
development of new diagnostic procedures, the mapping of the human genome and 
technological strides in biology have kick-started the march of personalized therapy into 
mainstream medicine. Nowhere is this more striking than in the arenas of cancer therapy.  
The trend in cancer therapy has been to move away from the traditional paradigm 
of treating tumors based on where in the body they originate to targeting them based on 
their genetic signatures and on the panoply of biochemical pathways that drive their 
reckless growth and spread. In a nod to personalized medicine, researchers are working 
toward cataloguing the plethora of mutations in the cancer genome. This multinational 
effort, called the International Cancer Genome Consortium, is aimed at documenting all 
possible mutations in 50 of the most common cancers by sequencing DNA from a 
minimum of 25,000 individual tumors.  
Diagnostic tools to illuminate the genetics of cancer have not only started to 
reshape patient care but have also influenced the development of novel, effective 
treatment options for patients. The goal of molecular diagnosis is to transform cancer 
from a death sentence into a manageable chronic condition. Starting with the 1960 
discovery of the genetic aberration called the Philadelphia chromosome in patients 
suffering from Chronic Myeloid Leukemia (CML), researchers have discovered a number 
of oncogenes and tumor-suppressor genes whose mutant forms trigger different types of 
cancer. That, in turn, has led to a handful of targeted drugs, like Gleevec and Tarceva, 
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which slam the brakes on runaway cell division in specific patient groups. Since 2001, 
more than 30 new cancer treatments have been approved by the U.S. Food and Drug 
Administration (FDA). Some of those are based on the molecular characteristics of 
individual tumors.  
For example, Novartis’ Gleevec, the poster-child cancer drug known by the 
generic name imatinib mesylate, inhibits an enzyme—tyrosine kinase—whose activity 
causes uncontrolled cell proliferation and CML in patients harboring a mutation in the 
gene implicated in that cancer. In some CML patients, however, Gleevec fails to work 
after a while because of the onset of additional mutations in the gene that render the 
enzyme resistant to the drug. For these patients, Bristol Myer Squibb’s cancer drug 
dasatinib was found to be effective against the majority of mutations conferring 
resistance to Gleevec, according an article published in 2004 in the journal Science. 
To develop such precisely targeted treatments for cancer, scientists require 
markers that would predict a patient’s response to therapy, the potential toxicity related to 
the treatment and prognosis. A small number of such markers guide cancer treatment in 
the clinic today. Indeed, they may be seen as a sort of barcode that’s used to distinguish 
one tumor from another, for example, a piece of cancerous brain from a nub of breast 
tumor. These markers are important to cancer care but their reliability and validity are 
debatable.  
On another front, diagnostic tools have transformed the treatment of infectious 
diseases. Timely and accurate diagnosis is essential to treating patients infected with 
little-known or hitherto unknown pathogens and for curbing the spread of infectious 
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diseases, thus serving an important public health function. Novel diagnostic tools for 
clinical use must be approved by the FDA. The agency discriminates between two types 
of diagnostics based on the analysis of DNA, or its chemical relative RNA: genetic 
diagnostics, which determines the presence or absence of a particular targeted DNA 
sequence already known to be related to a health outcome, and genomic diagnostics 
which measures gene expression, a term scientists use to describe gene activity, such as 
the production of proteins implicated in disease.  
The technology to develop diagnostics for infectious diseases is available, but it 
has not been widely applied to the diagnosis or detection of emerging infectious diseases. 
Emerging infections are new diseases that are constantly appearing in populations, such 
as Severe Acute Respiratory Syndrome, West Nile virus infection, drug-resistant forms of 
tuberculosis and tropical diseases like malaria. Standard diagnostic procedures for these 
neglected diseases are weak and unreliable, such as sputum microscopy, skin testing, and 
radiography for tuberculosis, and some are notoriously difficult to carry out, such as the 
microscopic techniques used to diagnose malaria. Microscopic diagnosis of malaria is 
subject to a great deal of variability that depends on the accuracy of the investigator. 
One promising diagnostic tool in the arsenal of infectious diseases specialists is 
called the microarray or gene chip. A gene chip is a short stretch of genetic material—
DNA or RNA—immobilized on a solid surface, such as a glass slide or a wafer of silicon. 
Chips are sensitive enough to detect subtle differences in the identity of pathogens that 
are much harder to spot with other molecular methods. Scientists use gene chips to detect 
the presence of disease-causing organisms in patients’ genetic material by matching the 
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genetic sequences on the chip with those found in the patients’ samples.  The unraveling 
of the genomes of many pathogens has allowed scientists to design chips to detect novel 
infectious disease agents.  Further, chips allow the simultaneous detection and analysis of 
thousands of snippets of genetic material in a single experiment.  
A particularly promising use of chips has been in the detection of viral diseases 
using the Virus Chip, developed by a young Californian researcher who helped the 
Centers for Disease Control and Prevention confirm the identity of a virus that wreaked 
havoc in large swaths of Southeast Asia. The Virus Chip helped determine that the virus 
that caused Severe Acute Respiratory Syndrome (SARS) was a novel member of the 
family of coronaviruses. Now, the chip’s designer is using the technology to help 
diagnose emerging infections. He is participating in the launch of a new center for the 
diagnosis and detection of hitherto unidentified pathogens. He hopes to make the new 
center available for routine clinical diagnosis and for the ongoing battle against emerging 
infections. But the chip’s story is also a cautionary tale about the challenges to the 
widespread adoption of microarray technology in the clinic.  
For people with mysterious illnesses whose pathology—and indicators of 
pathology—are elusive, the road to recovery is often long and tiresome. Buffeted by 
doubt, anxiety and a range of baffling symptoms, these patients are forever in a quest for 
a name for their condition. Many such conditions that have names are mired in 
controversy. Fibromyalgia, chronic fatigue syndrome and chronic Lyme disease are a few 
examples. While some physicians are convinced of the existence of elusive 
pathophysiological causes for these disorders, others argue that these conditions must be 
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treated with little or no medication. The U.S. National Institutes of Health (NIH) 
launched a new center in May 2008 to bring together a team of 25 physicians and 
scientists from the NIH Clinical Center and the National Human Genome Research 
Institute to address these questions under the umbrella of the Undiagnosed Diseases 
Program.  
Justification of Study 
While the mainstream media have touted personalized medicine as the wave of 
the future, many stories present the promise of personalized medicine using anecdotal 
victories without explaining the challenges to the success of the approach. Little more 
than short shrift has been paid to the role of molecular diagnosis in personalized 
medicine. As the articles listed in the bibliography of this thesis attest, The New York 
Times, The Washington Post, Newsday, New Scientist, Discover, Scientific American and 
The Scientist have covered personalized cancer treatment extensively, but the vast 
majority of the coverage has presented the promise of personalized medicine without 
commensurately exploring the shortcomings and the challenges to the approach. Some of 
these stories bear sensational headlines such as “A special drug just for you, at the end of 
a long pipeline,” “A drug to call one’s own,” and “Saving lives with tailor-made 
medication.” While the overall message these stories convey—that cancer treatment is 
moving away from an organ-centered approach to a patient-centered one—is powerful, 
tempering the message’s implicit optimism by laying out the caveats to personalized 
medicine is equally important. More importantly, few stories mention that personalized 
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medicine may not be a concept ready for prime-time. In that sense, these stories leave 
much to be desired. 
The role of novel diagnostics in treating infectious diseases, in identifying novel 
pathogens, and in curbing the spread of emerging infections is little known to lay 
audiences. A review of the mainstream media revealed fewer than a half-dozen news 
stories that discussed the role of chips in the diagnosis of infectious diseases in clinical 
and in epidemiological settings. Local media in the San Francisco Bay area, including 
The San Francisco Chronicle, The Sacramento Bee and The San Francisco Business 
Times, have covered the use of microarrays in infectious diseases, partly because of the 
proximity of these media outlets to the laboratory of Joseph DeRisi, who received 
recognition for his discovery of the Virus Chip. The New York Times did a short Q&A 
with DeRisi on the tool’s promise and on his future plans. But there haven’t been many 
news stories in the media that explain how microarrays could transform the diagnosis of 
mysterious infections; trade journals such as The Scientist and Science have explored the 
topic briefly. Fewer still are stories that explain the promise of microarrays as frontline 
screening tools that could help doctors rule out a large number of disease-causing 
organisms when faced with a sample from a patient suffering a condition of baffling but 
likely infectious origin. Journalists have seemingly shied away from some of those stories 
because of the complexity of medical language used in research. But medical 
breakthroughs and treatment should be covered and translated in a way that makes sense 
to average citizens and makes information useful to them in seeking diagnosis and 
treatment of disease.  
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Much needs to be covered within the broad subject of diagnosis in modern 
medicine. While the topics are many, this thesis will consider three aspects: developing 
research, direct application of knowledge and remaining questions. The thesis, a series of 
three articles, specifically explains the diagnostic challenges to personalized cancer 
therapy, the role of cutting-edge diagnosis in treating infectious diseases and the 
controversy surrounding the diagnosis of fibromyalgia. 
Literature Review 
Personalized medicine has become a buzzword; headlines tout the new movement 
as one poised to revolutionize medicine (Pollack, 2005; Roan, 2008; Dreifus, 2006; 
Grady, 2008). Former Health and Human Services Secretary Michael Leavitt said at a 
conference in Washington, D.C., in 2007, “Personalized healthcare will combine the 
basic scientific breakthroughs of the human genome with computer-age ability to 
exchange and manage data” (Fox, 2007). But what exactly is “personalized medicine”? 
According to Woodcock, it is “nothing more than what medicine has always been at its 
best – the careful evaluation of the health of an individual based on the best information 
obtainable about the person’s physical and mental state” (Woodcock, 2007).  
Traditional medicine works by generating diagnostic hypotheses, which set the 
context for testable predictions. If the enlarged and tender liver detected by physical 
examination indicates hepatitis (the hypothesis), specific liver tests should be elevated 
(the prediction). If not, the hypothesis needs to be discarded or substantially modified 
(Fauci et. al, 2005). One of the cornerstones of personalized medicine is the hope that 
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new diagnostics may help individualize therapy and transform its scientific basis – from 
trial and error to treatment based on pathological insight. 
Diagnosis in personalized cancer treatment 
In cancer treatment, novel diagnostic tools, such as the HER2 receptor test for 
breast cancer and the OLIG2 test for certain brain tumors, turn the focus on specific 
cellular targets for drug intervention. They also provide significant predictive value for 
treatment response, which has been demonstrated for drugs like Herceptin and Gleevec 
(Woodcock, 2007). Genentech’s Herceptin was the first personalized drug for breast 
cancer and is effective only in patients whose cancer cells produce the HER2 receptor, a 
protein that can be detected using approved diagnostic tests.  Novartis’ Gleevec, 
developed for CML patients but also used by patients with gastrointestinal stromal 
cancer, targets the genetic aberration called the Philadelphia chromosome, for which 
informational tests are available (Kling, 2007). But Herceptin and Gleevec have been 
lone players in a sluggish game. Only in recent years have a dozen or so pharmaceutical 
companies started developing diagnostic markers that guide prescribing. For example, the 
Amsterdam-based biotech firm, Agendia, offers a technology platform with 70 genes that 
serves as a mammaprint, or a prognostic tool for breast cancer recurrence following 
chemotherapy and radiation (Hayden, 2007). The UK-based biotech company, DxS, 
offers a tool that detects the presence of mutations predicting response to treatment with 
Imclone’s colon cancer drug Erbitux. In part, the push to develop novel diagnostic tools 
came from the demand for medicines of better value, the high cost of drug failures, and 
the revolution in genomics (Allison, 2008; Little, 2006).   
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The FDA’s handling of AstraZeneca’s lung cancer drug, Iressa, is an illustrative 
case study of the significance of diagnostic tests in guiding treatment choice. In 2003, the 
agency approved the drug based on a mere 10 percent response rate. But in light of new 
clinical data that emerged two years later, the agency revoked its approval and required 
the manufacturer to change the drug’s labeling to ensure that the drug was not given to 
anyone not already taking it; the data showed little overall clinical benefit. A reliable 
indicator of effectiveness—a biomarker—for Iressa is still unavailable, but the drug’s 
failure prompted pharmaceutical companies to find diagnostic markers for the cancer 
drugs in their pipelines (Allison, 2008). It is perhaps in this vein that the president of 
Massachusetts-based Genzyme Genetics, Mara Aspinall, said, “Diagnostics has been an 
overlooked, underappreciated asset in the healthcare environment” (Kling, 2007). 
Diagnostics may have long been the neglected step-sibling to drug discovery, but its 
growing importance in cancer treatment is reflected in the employment boom in an 
industry that is attracting biologists, chemists, biostatisticians, engineers and computer 
programmers to develop diagnostics (Hoag, 2004). 
One type of diagnostic marker helps in prognosis. Prognostic markers may be 
defined as factors—often genes or their protein products—that predict the outcome in the 
absence of therapy or that predict an outcome different from that of patients who receive 
therapy but who do not possess those gene variants or protein products. But many of the 
currently available prognostic markers for cancer are bedeviled by shortfalls. Many were 
identified in retrospective studies using available specimens instead of representative 
groups for different types of cancer, making them unsuitable to diagnose the wide 
biological variation found in tumors occurring in patients; many were discovered in 
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underpowered studies that had too few participants to reveal true clinical benefit; many 
were not validated in prospective trials; and for many, their prognostic impact was not 
shown to provide added clinical benefit (Duffy & Crown, 2008).  Currently, only three 
cancer markers predicting a likely response to a specific therapy are in widespread 
clinical use—estrogen receptor, progesterone receptor, and HER-2.  
A large number of cancer markers purportedly useful in diagnosis and screening 
are beset with problems of reliability and validity, in part because their diagnostic utility 
could not be reproduced when tested in large populations. Bias and chance plague the 
studies that led to the discovery of many markers, tempering the initial enthusiasm of the 
scientific community and media outlets (Ransohoff, 2007). 
Further, some cancer biomarkers are unreliable because researchers analyzed 
cancerous and noncancerous tissues on separate days using machines that didn’t always 
give reproducible results. Other biomarkers were discovered in studies in which scientists 
compared apples and oranges: One biomarker for prostate cancer was discovered in a 
study in which the researchers compared blood from 67-year-old men with prostate 
cancer with blood from 47-year-old women. In such studies, experts argue, bias rather 
than a biomarker might explain the observed differences between individuals with and 
without cancer (Ransohoff, 2007). 
While such studies may pass enough scientific muster to sneak through the peer 
review process in scientific publishing, the biomarkers that they identify are unlikely to 
benefit most patients. 
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Even those biomarkers routinely used for predicting prognosis are far from 
perfect. Estrogen receptor, a protein used to predict response to hormone therapy for 
breast cancer, was discovered in a review of patient data from worldwide clinical trials. 
The review found that more than half of patients whose cancer cells overproduced the 
estrogen receptor responded to hormone therapy, while those whose cells did not 
overproduce the estrogen receptor had little chance of responding. That led to a widely-
used laboratory test for the receptor. But oncologists have since questioned the test’s 
reliability, citing that the test could be wrong as many as four times out of ten. Further, 
new evidence uncovered since the test’s adoption suggests that it’s not just the amount of 
receptor in cancer cells that is crucial for predicting prognosis but also the amount of the 
receptor’s precursor—a molecule, called estrogen receptor messenger RNA, which 
carries the recipe for making the receptor. The test does not measure the amount of 
messenger RNA in cancer cells (Duffy & Crown, 2008). 
Other quantitative tests have entered the scene since the estrogen receptor test was 
introduced. Oncotype DX, a prognostic test manufactured by California-based Genomic 
Health, measures the activity of 16 cancer-associated genes to predict the risk of 
metastasis—and, therefore, of recurrence—in breast cancer patients receiving the 
chemotherapy drug tamoxifen. Mammaprint, a prognostic test manufactured by 
Amsterdam-based Agendia, rummages through 70 genes in patients’ tumor samples to 
predict the risk of cancer’s recurrence in newly-diagnosed breast cancer patients 
(Henderson, 2007). 
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The FDA has approved Mammaprint for use in predicting the likelihood of cancer 
recurring for certain breast cancer patients, but the agency has not approved Oncotype 
DX, which continues to be used as a test unregulated by the FDA. Tests can be offered by 
laboratories without FDA permission, even as scientists work toward validating them. 
But both those tests have problems. Based on patients’ genetic profiles, the tests either 
group patients into three categories—high, intermediate and low risks of cancer 
recurrence—or provide a specific number between zero and 100 that represents patients’ 
risk of cancer recurrence. The test predicts this risk from the association between genetic 
profiles and cancer recurrence that scientists have observed among thousands of cancer 
patients in past clinical trials. Doctors use the risk information to decide whether a patient 
might benefit from chemotherapy. While patients in the low and high risk categories are 
likely to get an unambiguous answer to that question, patients in the intermediate risk 
category are left wondering whether they should undergo chemotherapy (Henderson, 
2007). 
Therein lie the problem and the solution. Diagnosis plays a pivotal role in cancer 
treatment because even small genetic variations between individual patients could mean 
the latest blockbuster cancer drug for a particular cell type could be a lifesaver to one 
patient while being lethal to another. These genetic variations may alter the behavior of 
cellular proteins that carry drugs to their targets, curtail enzymes that render drugs 
functional, block drugs from binding to their targets, change how well a drug is tolerated, 
and determine the overall bodily response to the drug (Abbott, 2003).  Much of that 
variation lies in single letter changes in the genetic code, called Single Nucleotide 
Polymorphisms, or SNPs. These changes have been known to allow toxic cancer drugs to 
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linger in the body at dangerous levels instead of conferring the intended benefit. But 
here’s the rub: For a multifactorial disease like cancer, often described as a constellation 
of diseases, identifying the variations that could potentially affect the patient’s outcome 
presents a challenge of leviathan proportions (Katsnelson, 2005; Geddes, 2008). 
To be sure, comprehensive studies have found a small number of SNPs as 
statistically strong prognostic markers for certain cancers. For example, specific SNPs in 
genes such as p53, estrogen receptor, progesterone receptor, BRCA2, and the proto-
oncogene HER-2 have been shown to predict the risk of breast cancer and response to 
therapy. A few other markers are also used occasionally. Cytochrome c, a protein 
released by dying cells, has also been used as an indicator for ongoing cell-death induced 
by cancer drugs. Fragments from the cellular backbone, or cytoskeleton, have been used 
as signs that certain cancer drugs are producing their intended effect (Anderson et al., 
2006). Robert Lipschutz, vice-president of California-based biotech giant Affymetrix, 
says to develop tests that guide therapy based on genetic variations, one would have to 
assay millions of genotypes from different patients, making the analysis unsuitable for a 
clinical trial setting. However, he says, chips and other sophisticated technologies could 
bring the detection of such genetic variation within the realm of possibility (Lipschutz, 
1996). Some scientists are even proposing a follow-up to the Human Genome Project: 
creating global consortia to archive group and individual patient genotypes and drug-
response phenotypes (Gurwitz, Lunshof & Altman, 2006). 
Mining the genetic data within tumor cells is no easy feat. Researchers deploy 
three broad strategies aimed at finding the connections between the patterns of gene 
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activity within tumor cells and the cells’ behavior. The first is the data-driven approach, 
in which a genome-wide analysis of gene expression, or the process by which genes 
produce proteins implicated in cancer, helps establish correlations between tumors and 
their likely response to therapy. The second is the knowledge-driven approach, in which 
tumors are probed for suspect genes based on the scientific literature. The third is the 
model-driven approach, in which the activity of genes after exposure to a specific 
stimulus—often a candidate drug—is used to predict response in the laboratory. Each 
method has its drawbacks: The data-driven approach relies on the quality of the data and 
the samples; the knowledge-driven approach is only as good as the state of the 
knowledge; and the model-driven approach might not accurately reflect what happens in 
tumors in the human body since the results of the approach are obtained in laboratory 
settings (van’t Veer & Bernards, 2008). 
One significant hurdle in biomarker-driven decision-making for drug 
manufacturers is the lack of quantitative information about how hard a target needs to be 
hit to obtain an optimal amount of therapeutic benefit. For example, the right dose of the 
chemotherapeutic drug for acute lymphoblastic leukemia is determined based on the 
patient’s thiopurine methyltransferase gene. When administered, the drug is inactive and 
must be transformed in the patient’s body into its active form. That transformation, 
brought about by the patient’s methyltransferase enzyme, depends on how much of the 
enzyme the patient’s cells make, and thus the drug depends on the activity of the gene 
that produces the enzyme. But the number of cancer drugs for which targeted dosing 
information is available is small (Lesko, 2007).  Even when all else works with 
clockwork precision—as is almost never the case—cancer cells often develop resistance 
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to individual drugs, a problem that might be overcome by administering drug cocktails 
which contain a mix of different drugs; when one drug fails, another takes over for a 
while (Ikediobi, 2008; Geddes, 2008).  
Currently, genomic analysis of patient samples occurs in no more than 30 percent 
of early-stage drug development programs, according to a report on personalized 
medicine from the United Kingdom’s Royal Society (Branca, 2005). The challenges to 
developing useful cancer markers are many, but there is reason for optimism. Systematic 
evaluation of candidate markers in distinct phases, adherence to evidence-based 
guidelines, and attention to appropriate study designs could lead to the development of 
truly useful markers (Ransohoff, 2007; 2008). 
So, some scientists suggest that drug developers follow a pharmacologic audit 
trail, consisting of a series of questions, while designing tailor-made cancer drugs: What 
is the status of the molecular target in the patient? Will enough of the drug be retained in 
the patient’s blood to hit the target? Will the drug be specific to the target? Will hitting 
the target disrupt the right downstream biochemical pathways? Will that disruption 
produce the intended biological effect? Will that effect result in a desirable clinical 
response? (Collins & Workman, 2006).  
Those questions are among the hardest to answer. That’s why Mervyn Turner, the 
chief strategist for Merck & Co., recently said, “The early stage of drug development has 
been democratized, but late stage clinical development is a tyranny” (personal 
communication). Further, segmenting patient populations to reduce genetic heterogeneity 
is challenging to drug companies, which typically prefer to target the largest possible 
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markets. Studying why some patients respond to certain drugs is a gamble for drug-
makers who have no way of knowing the size of the responder population before millions 
of dollars are spent (Million, 2006).  That said, patient genetic information could help 
pharmaceutical companies design better clinical trials, weeding patients progressively 
and reducing the overall cost of developing safer, more effective drugs (Marshall, 1997; 
Berenson, 2005).  
Stumbling blocks to personalized cancer treatment loom large in the minds of 
patients and physicians, too. Many of the new-wave diagnostics are expensive. Compared 
to the $48 that U.S. Medicare pays for a HER-2 test for response to herceptin for breast 
cancer treatment, some novel diagnostic tools can cost in the thousands of dollars (Baker, 
2006). While some insurance companies are willing to pay a higher price for novel 
diagnostics because they potentially reduce the overall cost of cancer treatment, many 
cancer patients don’t have private insurance (Kling, 2007; Pollack, 2004). The U.S. 
health care system is too fragmented to integrate predictive risk information into 
treatment over an individual’s lifetime (Deverka, Doksum & Carlson, 2007). Constrained 
by the amount of time available at the point of care, the average physician might be 
unable to embrace the use of diagnostics—assuming the tests are proven reliable and 
valid—while providing care (Levy & Young, 2008). Issues of confidentiality, privacy, 
malpractice, and genetic discrimination riddle the new movement (Reilly, 2001).  
Diagnosis in infectious diseases 
Many clinicians are familiar with a scenario in which a previously healthy patient 
develops a life-threatening illness bearing the hallmarks of infection but has negative 
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diagnostic test results. In 1996, the Centers for Disease Control and Prevention (CDC) 
launched the Unexplained Deaths Project as a systematic effort to analyze such cases. 
The project’s early reports found that fewer than two per 100,000 people in the U.S. are 
affected by such illnesses and that molecular analysis revealed the signatures of 
pathogens in those patients (Relman, 1999). 
While personalized medicine, the notion of tailoring therapy based on patient 
characteristics, has been slow to integrate novel diagnostics into routine clinical practice, 
the study of infectious diseases has benefited from an explosion of diagnostic technology. 
Surveys have indicated that less than one percent of all known microorganisms can be 
cultivated in the laboratory; the rest require the use of molecular methods for 
identification. This situation occurs partly because scientists are unaware of the precise 
environmental conditions that support the growth of microbes and are, therefore, unable 
to replicate them in the laboratory.  
Recent improvements in technology have revolutionized research and clinical 
management of infectious diseases. The Human Genome Project and efforts to unravel 
the genomes of pathogens have provided insights for developing tools to detect elusive 
and novel pathogens. One of those tools, called the microarray, is widely used in research 
settings because it allows the rapid, simultaneous analysis of thousands of genes. A 
microarray may be defined as a solid substrate, such as a silicon wafer or a glass slide, on 
which short strings of genetic material from the pathogen, called probes, are attached. 
Matches between the genetic material found in a patient’s sample and the strings 
immobilized on the substrate are used to determine the identity of the pathogen afflicting 
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the patient (Bryant, Venter, Robins-Browne & Curtis, 2004). The probes, which are short 
strings of the chemical compounds that compose genetic material, are complementary to 
thousands of genes of both known and unknown function. Depending on the object of the 
analysis, tailor-made microarrays contain probes that are designed to detect one kind of 
pathogen over another. The process works thus: DNA prepared from a patient’s body 
fluid or tissue sample is passed on the microarray. A scanner picks up any matches, 
which are then analyzed to reveal the genetic identity of the DNA found in the patient’s 
sample (Bryant et al., 2004; Ramsay, 1998). The choice of probes for a microarray 
depends on the sample being tested: It would make little sense, for example, to test DNA 
from a patient’s gastrointestinal sample on a microarray containing probes from 
respiratory viruses. Microarrays can be used to identify a pathogen, discover novel 
pathogens, predict outbreaks, track the evolution of pathogens over time, and analyze the 
virulence and invasiveness of pathogens. They can also be used to predict the 
development of resistance to antimicrobial drugs among known pathogens (Clewley, 
2004). 
Today, most microarrays used in clinical settings are developed by a small 
number of biotechnology firms, like California-based Affymetrix and Massachusetts-
based Millenium Pharmaceuticals. Some researchers put together home-made 
microarrays for specific needs (Mikhailovich, Gryadunov, Kolchinsky, Makarov & 
Zasedatelev, 2008). The high sensitivity of microarrays allows the speedy diagnosis of 
infected patients, especially when the levels of the pathogen in the patients’ bodies are 
low (Mahony, 2008). Microarrays are now routinely used to detect respiratory bacterial 
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pathogens, respiratory viruses, papillomaviruses, gastrointestinal viruses, and potential 
biological warfare agents (Loy & Bodrossy, 2006).  
One striking example of the use of microarrays was in the identification of the 
SARS virus as a novel member of the family of coronaviruses. In 2003, Joseph DeRisi, a 
molecular biologist at the University of California, San Francisco, helped the CDC 
confirm the identity of the virus using a tailor-made microarray that came to be widely 
known as the Virus Chip (Elias, 2003). DeRisi’s chip, an ordinary 1-by-3 inch 
microscopic glass slide on which 22,000 different viral probes had been spotted, could 
simultaneously screen for more than 1,000 different families of viruses, representing 
virtually every virus known to biologists at the time. Because viral DNA from patient 
samples will bind to the probes even when there isn’t a perfect match, new relatives of 
known viruses can be identified as belonging to a particular family (“Gene chip for viral 
discovery,” 2001).  Former CDC director Dr. Julie Gerberding hailed the device as “the 
absolute state-of-the-art probe for viral genes” (Russell, 2003).  DeRisi designed and built 
the robot that made the chip, and with help from a friend at the Massachusetts Institute of 
Technology, he wrote the software to automate the robot. 
After the initial success with the SARS virus, DeRisi used the device to identify 
the virus that was causing a novel wasting disease in parrots, macaws, and cockatiels. He 
decided not to patent his chip, preferring instead to disseminate the technology (Dreifus, 
2008). His chip has since been used to identify a virus, previously found only in mice, as 
the cause of prostate cancer in some men with a specific genetic defect known to confer 
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susceptibility to the disease (Maugh, 2006; Elias, 2006). DeRisi has also used the chip to 
detect respiratory viruses in a clinical setting (Wang et al., 2002). 
Despite the few success stories with microarrays, less than nine percent of all 
manufactured arrays are used in diagnostics, the rest being used for basic research 
(Striebel, Brich-Hirschfeld, Egerer, Foldes-Papp, 2003). Aside from the high cost, the 
difficulty of making microarrays with a sufficiently large number of probes is a hurdle to 
researchers. Furthermore, the quality of microarrays affects the reproducibility of their 
performance. That’s why the FDA created the Microarray Quality Control consortium in 
2005 (Jordan, 2007). 
Although microarrays have helped researchers make inroads into microbial 
diagnostics, they have not changed the diagnosis of emerging infections, such as drug-
resistant tuberculosis and malaria. Tests for pathogens causing these diseases are 
antiquated, inaccurate, and inadequate. For tuberculosis, the inadequacy of the standard 
diagnostic tests—sputum microscopy, skin testing, and radiography—is well 
documented. These tests suffer from low sensitivity, poor predictive value, and long 
processing times. Evaluation of drug resistance in tuberculosis patients takes at least four 
weeks, delaying treatment and sometimes leading to the administration of ineffective 
drugs that worsen the problem (Mikhailovich et al., 2008). But the availability of the 
complete genomic sequence of Mycobacterium tuberculosis has now created 
opportunities for developing novel diagnostic tools for the disease.  
For malaria, microscopic evaluation of blood samples is not only difficult but 
highly variable depending on who performs the diagnosis. Experienced microscopists 
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disagree on their diagnosis of up to a third of all microscopic slides (Perkins & Small, 
2006). But microarrays for the malarial parasite Plasmodium are just beginning to be 
developed in research labs. Indeed, DeRisi pioneered the development of a chip that 
could shed light on the developmental stage of the parasite in a patient’s blood, gene 
activity within the parasite in the blood, and the likelihood of drug resistance. He 
suggests that investigators’ unfamiliarity with the details of microarray technology might 
be an initial deterrent to the widespread adoption of this technology in the laboratory. 
However, he predicts that it won’t be long before every parasitologist will have easy 
access to malaria chips in a reliable and affordable form (Rathod, Ganesan, Hayward, 
Bozdech, DeRisi, 2002). 
Diffusing the technology among researchers is not the same as promulgating its 
use among clinicians. Developing countries, in which diseases such as malaria and 
tuberculosis are widespread, can hardly afford the high-priced technology. Hence, public-
private partnerships may be the solution. For example, The Foundation for Innovative 
New Diagnostics based in Geneva, Switzerland, is one such entity, whose goal is to 
identify the most promising diagnostic candidates for diseases of the developing world; 
accelerate development, testing, approval, distribution, and incorporation into routine 
clinical care; and help contain neglected public health scourges (Perkins & Small, 2006).  
DeRisi’s technology has not yet found its way into the clinic because of its cost. 
But it’s not because the chip would be too expensive that venture capitalists are loath to 
invest in it. It’s because it’s too cheap: A single commercial version of the chip would 
cost $50 per test. That’s too little return on investment to interest investors, who typically 
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chase diagnostic tests that cost $3,000 a run (Levine, 2006). But a cheap diagnostic test 
that provides significant clinical benefit might make up in volume if used in cases where 
millions are affected. Further, such a tool could lower health care costs by reducing the 
overprescription of antibiotics and by curtailing drug resistance. DeRisi is now 
participating in the launch of a new center for the diagnosis of emerging infections at the 
University of California, San Francisco. He hopes that the use of his chip technology at 
the center would be a step toward integrating the use of microarrays in the diagnosis of 
emerging infections in the clinic and in public health settings. The challenges to that 
effort are many, but he predicts it won’t be long before they are overcome (Dahlberg, 
2008). 
The tyranny of non-diagnosis 
Diagnostic techniques may have begun to transform medicine, but for some 
patients, the transformation yields few answers in their search for names for conditions 
without clearly identifiable physiological bases. These undiagnosed conditions may 
manifest themselves differently but are often unified by a common narrative: widespread 
pain, fatigue, flu-like symptoms, and a loss of zest. Chronic fatigue syndrome, 
fibromyalgia, and irritable bowel syndrome are a few examples of diseases for which the 
physiological bases are hotly debated. Patients in search of a diagnosis for mysterious 
conditions are often confused by a lack of consensus in the medical community. While 
some doctors suggest that it’s only a matter of time before the underlying pathology 
surfaces, others argue that many of these conditions shouldn’t be treated as medical 
disorders because they have no known organic cause and that they are better managed by 
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psychotherapy. Allegations and actual instances of disease mongering by drug makers 
have only fueled the debate (Hadler, 2008). In May 2008, the NIH launched its 
Undiagnosed Diseases program to help patients in search of a diagnosis. The program, 
supported by 25 scientists from the NIH Office of Rare Diseases and the National Human 
Genome Research Institute, invites applications from patients who have waited for years 
for a diagnosis despite ongoing consultation with a primary care physician (Keim, 2008).  
The debate over whether such an effort is worthwhile rages on, as patients continue to be 
whipsawed by doubt and optimism. 
On one side of the debate, experts argue that technological handicaps and 
physicians’ approach to disease may hinder accurate diagnosis. In his book Second 
Opinions, Dr. Jerome Groopman explains how clinical decision making would be a well-
defined, scientific exercise in a predictable world. He argues that physical and emotional 
responses to each illness can be as varied as the personalities of the afflicted. “This means 
that diagnosis cannot be strictly bound by generic recipes, but must be made individual,” 
he suggests. He undertakes a lengthy treatment of the phenomenon of reactivation of 
exotic microbes years after infection as a cause of bizarre, episodic symptoms 
characterized by fever, fatigue, and fogginess. He provides a brief description of the 
weekly clinical conferences where Harvard specialists discuss the toughest cases by 
creating lists of possible causes. Then, he introduces the concept of idiopathy – “a 
wastebasket term applied to disease conditions whose origins were not known.” He 
cautions against the use of the term, which might imply that “you are satisfied with your 
ignorance and ready to stop searching further for a discrete cause” (Groopman, 2007). 
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Some scientists note that the art of making a diagnosis has its shortfalls. Using 50 
instances of pathology examined at medical conferences, Doctors Eddy and Clanton 
distill the essence of diagnosis to the following: “aggregation of groups of findings into 
patterns, selection of a pivot, or key finding, generation of a cause list, pruning of the 
cause list, selection of a diagnosis, and validation of the diagnosis.” Although its 
systematic and often thorough nature makes pattern recognition a valuable technique for 
honing in on a patient’s condition correctly, they suggest that pattern recognition ignores 
the inability of the human mind to juggle and weigh multiple probabilities on the spot 
(Eddy & Clanton, 1982). 
On the other side, experts argue that social construction and patients’ inability to 
cope with innocuous symptoms underlie many mystery disorders (Hadler & Greenhalgh, 
2004). Rheumatologist and author of the book, Worried Sick, Dr. Nortin Hadler argues 
that putatively scientific treatments for conditions without clear biological bases might 
only thrust patients deeper into a downward spiral of distress. “All the while, the 
treatment act is plying the patient with intimations to the pathophysiology of their 
nociception. That is how the person suffering persistent widespread pain learns to be a 
patient with Fibromyalgia (FM)… The patient is changed forever. Their narrative is laced 
with the clinical heuristics they have learned, which they can recite with objectivity that 
approaches dispassionate,” (Hadler, 2003). 
Further, doctors’ approach to clinical diagnosis might perpetuate such disorders. 
Dr. Sherwin Nuland, a professor of surgery at Yale University and author of popular non-
fiction books, recounts the writings of French literary savant Voltaire and the first 
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modern physiologist Claude Bernard to illuminate an axiom doctors must grapple with 
throughout their professional lives: “[a physician] should never allow himself to forget 
for a moment how it can lead him astray while caring for any one sick person, whose 
situation may present riddles that differ from everything else he has learned at the 
bedsides of so many others.” Nuland discusses seven important factors that govern 
physician judgment during the process of diagnosis: the urgency of the situation, the 
evolutionary pattern of the disease in the individual in question, the facts of the pathology 
as they unravel, inferences made from the facts, the patient’s emotional and biological 
response to illness, the circumstances of the patient-physician encounter, and the 
physician’s own sociocultural baggage. He suggests that the rush to label a disease might 
sometimes cause physicians to treat psychosocial problems as medical disorders (Nuland, 
2008). 
Amid the debate, patients with undiagnosed disorders suffer. In the book The 
Lonely Patient, physician-writer Dr. Michael Stein takes readers into the emotional 
landscape of patients battling illnesses. He tells the story of disease from the patient’s 
standpoint, giving readers a glimpse of the rollercoaster ride patients are unwillingly 
thrust into from the moment they are given a diagnosis. This ride is marked by feelings of 
betrayal, anger, loss, terror, and loneliness. The patient’s story also explains the 
importance of paying mind to the “idiom of the ill.”  
Stein writes, “Each patient’s emotions seemed just slightly out of my reach. I was 
inarticulate about the patient’s experience of illness, but I was also holding back, in part 
because of my training and in part because I believed I didn’t have the right to ask or 
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intrude.” Stein suggests that the clinical information-gathering process, the physician-
patient interview, and clinical diagnosis proper may be key factors in addressing patients’ 
problems (Stein, 2008). 
Some scientists suggest that classical theories of persuasion and rhetoric may help 
physicians evaluate patient complaints for which no objective evidence exists and which 
depend uniquely on the persuasive power of patients to be taken seriously (Segal, 2007). 
They propose ways in which physicians might convince patients that nothing is wrong 
with them and that medical intervention would possibly cause more harm than good.  
The journey through this two-way street—towards and away from diagnostic 
labels—is fascinating at the very least, and exasperating at best. On the one hand patients 
trying to find a label for their own conditions are called by some doctors “anxiety-
ridden,” “know-it-all,” “refuseniks,” and “malingerers.” On the other hand are experts 
who believe that labeling misery is hardly a solution to such mysteries (Segal, 2007; 
Hadler, 2003).  
 Research Questions 
As the literature review shows, there are a number of ways in which diagnosis 
plays a crucial role in the practice of medicine, in particular in the development of tools 
for personalized medicine, in the treatment of infectious diseases and in tackling 
controversial diseases. A survey of the mainstream media reveals that many stories 
merely skim the topic. The purpose of this series of articles, which would be suitable for 
a publication such as Scientific American, is to elucidate the central role of diagnosis in 
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medicine and to show how advances in diagnostic technology have improved the 
treatment of certain diseases while yielding little benefit to the treatment of others. The 
thesis specifically seeks to answer: 
1. What are the challenges to developing diagnostic markers for truly 
personalized cancer therapy? 
2. How have recent advances in molecular diagnostics transformed the 
treatment of infectious diseases, especially emerging infections caused 
by novel viruses? 
3. What happens when doctors cannot diagnose a disorder? What is the 
plight of patients suffering from disorders whose very existence is 
controversial? 
 Methodology 
To answer these questions, the series is divided into three stories. The first feature 
story in the series serves as a piece of explanatory writing that presents the nuts-and-bolts 
of diagnosis in personalized cancer treatment and the challenges to developing tailor-
made medications. It attempts to explain the significance of diagnostic markers while 
addressing the challenges to developing them. The story on biomarkers for cancer 
treatment presents case studies of patients receiving such treatments with interviews with 
cancer researchers at leading institutions providing personalized care. 
The second feature serves as a trends-cum-analysis piece that offers an in-depth 
look into the state-of-the-art of diagnosis of infectious diseases. It looks at diagnostic 
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chips for the diagnosis of emerging infections, including interviews with the pioneer of 
the Virus Chip technology, Joseph DeRisi, a molecular biologist at the University of 
California, San Francisco, and Dr. Charles Chiu, an infectious diseases specialist, who 
will head the new center for the diagnosis of emerging infections at the University of 
California, San Francisco.  
The third and final feature of the series poses the question: What happens when a 
disease cannot be diagnosed in the clinic? This feature story looks into the life of a 
patient battling an undiagnosed condition. It serves as a representative profile that also 
presents the long festering debate over the treatment of mystery illnesses. To illustrate a 
story on mystery illnesses, interviews focus on the experience of 24-year-old Kerry 
Brewer of Cary, North Carolina, the daughter of a former government attorney, who went 
from being a successful track-and-field athlete to what some might call a professional 
patient. In the last two years, she has seen more than 30 doctors and has taken a dizzying 
list of medications, to little avail. Diagnosis still eludes her. This piece is written in the 
form of narrative nonfiction instead of following the traditional journalistic style. 
Narrative nonfiction applies the techniques of fiction—characterization, detail, 
description, and extended anecdotes—to journalistic accounts. This story includes 
interviews with Brewer’s doctors and independent experts who provide context and 
address the broader, universal theme of elusive diagnosis. 
In a fourth chapter, the author includes his observations on the importance of 
diagnosis in three subject areas -- personalized cancer treatment, emerging infections and 
controversial illnesses. Also included are some recommendations for additional stories as 
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well as guidance to reporters who take on the task of writing about complicated medical 
topics for lay audiences. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
CHAPTER II 
 BIOMARKERS IN CANCER TREATMENT 
Editor’s Note: This series of feature stories consists of three articles on the role of 
diagnosis in modern medicine. Traditional and modern methods of diagnosis affect 
treatment choices for patients and have a big impact on health care delivery and costs. 
The first story explains the diagnostic challenges to tailoring cancer treatment to 
patients’ genetic makeup. The second story discusses the role of cutting-edge diagnosis in 
treating infectious diseases, and the third explores the controversy surrounding the 
diagnosis of fibromyalgia. Together, the stories represent three facets of diagnosis – the 
challenges, the promise and the conflicts surrounding this essential part of medical 
practice. This is the first of three stories. 
One morning in August 1999, Patricia Spears, 50, noticed a lump on her breast 
and another in her armpit. Two weeks later, the lumps were still there. A research 
technologist at North Carolina State University in Raleigh, N.C., Spears was almost sure 
of the diagnosis. A visit to oncologist Dr. Becky Campbell at Rex Cancer Center in 
Raleigh confirmed her fears. 
“The ultrasound and mammogram revealed that what I had was most likely a 
malignancy,” Spears says. Two days after the mammogram, Campbell ordered a biopsy
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 of the lump on Spears’ breast, but her doctor didn’t think there was any need to wait for 
the results before beginning treatment. 
“My oncologist said, ‘It looks like a duck, quacks like a duck, so it is a duck,’ and 
suggested I start chemotherapy as soon as I could get an appointment,” Spears says. 
 A week later, Spears started chemotherapy, a mix of drugs – adramycin, cytoxan 
and taxol – commonly prescribed to breast cancer patients at the time. The regimen 
worked, although Spears endured a range of side effects, including nausea, fatigue, pain, 
rashes, and an anaphylactic reaction to taxol. The lumps in her breast shrank before 
disappearing eight weeks after her diagnosis. 
Spears’ biopsy report came back a week after she had started chemotherapy. It 
showed that two proteins implicated in breast cancer—estrogen receptor and 
progesterone receptor—were absent in her cancer cells. The report also showed that her 
cancer cells overproduced HER2, a protein that promotes the growth and multiplication 
of cancer cells, making the cancer aggressive and difficult to treat. Spears’ doctor didn’t 
switch Spears’ therapy based on this genetic information because there weren’t better 
alternatives to the cancer drugs Spears was taking. 
That was in 1999. 
Today, the same information would have put Spears in a category of patients 
eligible to get the cancer drug trastuzumab, known by Genentech’s brand name 
Herceptin, and might have spared her the slew of side effects that she endured. Herceptin 
is an antibody that targets the HER2 protein in cancer cells, blocking the protein’s 
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function and sending the cancer cells on the fast track to death. The antibody is given 
alone or along with chemotherapy to patients whose tumor cells overproduce the HER2 
protein. According to the National Cancer Institute, Herceptin slashed by half the risk of 
cancer returning in patients who took the drug along with chemotherapy compared to 
patients who got chemotherapy alone. However, the drug has caused congestive heart 
failure in some patients. 
“At that time, Herceptin was only given to women with metastatic disease, so I 
didn’t qualify for that. Today, oncologists know that these kinds of tumors respond better 
to Herceptin,” says Spears, whose cancer hasn’t recurred. 
Herceptin is among a growing class of targeted cancer drugs that includes other 
bestsellers such as Novartis’ Gleevec for stomach cancer, Genentech’s Avastin for breast 
cancer, and Genentech’s Tarceva for lung cancer. Some patients and doctors have hailed 
these drugs as harbingers of hope for cancer patients because the medications work by 
exploiting molecular differences between cancerous and normal cells. Others have 
reviled the drugs as medications that help patients eke out a few extra months of life at a 
huge cost.  
To develop some of these drugs, researchers relied on specific molecules in 
cancer cells that help scientists diagnose cancer. These molecules, called biomarkers, lie 
at the heart of modern cancer treatment.  
Biomarkers are essentially fingerprints. They may be proteins found in the blood 
or tissues of cancer patients, or genes in cancer cells. Scientists take samples of cancer 
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from different patients to develop a fingerprint for each cancer type. The hope is that the 
fingerprint—a basis with which to compare new patient samples—would help doctors 
group patients based on the kind of cancer they have.  
Thus, doctors can use biomarkers to detect early-stage cancer before patients 
experience symptoms and to assess the likelihood that a cancer will recur. In addition, 
doctors use biomarkers to group patients for treatment and to predict patients’ response to 
treatment. 
Biomarkers are among oncologists’ vital tools in the war against cancer, but a 
common problem besets most biomarkers: They are unreliable. 
While scientists have discovered a handful of biomarkers for different types of 
cancer, most have not found widespread use in the clinic because their usefulness has not 
been demonstrated in clinical trials involving large numbers of cancer patients. Most 
biomarkers were discovered in studies of tumor samples from patients by comparing the 
tumors with tissues from normal individuals. But here’s the rub: The tumors and normal 
tissues used for biomarker discovery were sometimes handled differently or came from 
different clinics. 
Dr. David Ransohoff, a professor of medicine at the University of North Carolina 
at Chapel Hill, says scientists have trouble determining the uniqueness of each 
individual’s cancer at the genetic level. No one knows all the ways in which a given kind 
of cancer could manifest itself among patients. So, Ransohoff says, the biomarkers in use 
aren’t truly representative of the cancer types for which they were developed. That’s 
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because laboratory researchers didn’t always use enough samples of tumor tissues for 
each type of cancer during the discovery of biomarkers. “Depending on which patients 
were chosen for specimen collection the markers may be meaningful or totally 
meaningless,” Ransohoff says. 
Ransohoff says a more reliable way to discover cancer biomarkers would be to 
follow a large group of healthy individuals over time and periodically collect samples 
from them. Scientists could then compare the cancer cells of those who develop cancer 
with the cells of those without cancer to pinpoint differences.  
Dr. Neil Hayes, a UNC-Chapel Hill oncologist, says obtaining enough tumor 
tissue is the number one hurdle facing the discovery of biomarkers. Hayes participates in 
a nationwide consortium—Cancer Genome Atlas Network—to catalog all the genetic 
abnormalities in cancer. The network has started work on a kind of brain tumor called 
glioblastoma. Scientists in the network have set up in Phoenix, Ariz., a repository of 
cancer tissues from patients across the country. The repository houses tissues and blood 
samples from thousands of cancer patients, but that’s far fewer than what scientists need 
to represent the genetic variability occurring in populations, Hayes says. 
Developing truly useful biomarkers might require collaboration between a 
number of institutions and regulatory agencies. “Biomarker development has received 
much less attention than drug development,” Ransohoff says. There are no existing 
guidelines for developing biomarkers into tools useful in the clinic. “There is not much 
consensus in this field. It’s a very difficult area, and a lot of people are wandering around 
in this desert,” he adds. 
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For predicting response to drugs, Ransohoff says, drug companies could develop 
biomarkers concurrently with drugs. “It’s easy to piggyback studies of prognostic 
markers onto the clinical trials of cancer drugs,” he says. 
“It’s a chicken and egg situation. To develop the drug, you often need a marker, 
but developing the marker ahead of the drug can be a real challenge,” says Sharyl Nass, a 
breast cancer researcher at the National Academy of Sciences, who was one of the 
authors of a report on cancer biomarkers published by the Institute of Medicine in 
Washington, D.C.  
Dr. Kimberly Stegmaier, a pediatric oncologist at Dana-Farber Cancer Institute in 
Boston, Mass., is trying to combine biomarker and drug discovery in the laboratory. 
Stegmaier identified a small chemical compound that altered the activity of certain 
cancer-associated genes in the blood cells of patients with a rare but fatal form of 
childhood leukemia, called acute myeloid leukemia, or AML. Children with AML have a 
survival rate of 50 percent. She is now testing the compound in a clinical trial for AML 
patients. 
Stegmaier identified the genes that the compound targeted by using a technology, 
called microarrays, that sifted through thousands of genes in normal and cancerous blood 
cells and spotted differences between the two cell types. 
“We asked ourselves whether we could use gene [activity] as a biomarker, in 
essence, in response to a chemical compound in the laboratory. This is not the classic 
way of using biomarkers in patient samples to predict response to therapy,” Stegmaier 
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says. “The ultimate hope is that we would be able to translate our findings to predict gene 
[activity] patterns that would predict response to drugs in the patient.” 
If such a drug were to prove safe and effective in trials, it could significantly 
extend the lives of children with AML. 
A number of challenges temper that hope. Stegmaier says one of the biggest 
challenges is determining how unique each individual’s cancer is. Further, she echoes 
Ransohoff’s concerns, “Technical issues with sample handling and processing could 
cloud data interpretation. That’s a huge problem.” She says pediatric cancers often pose 
an additional problem: Patients’ tumors provide too little tissue for large-scale studies of 
biomarker discovery. 
Despite these hurdles and the lack of guidelines, scientists everywhere are forging 
ahead with efforts to discover new cancer biomarkers. Only a handful of those freshly 
minted biomarkers are likely to be validated, and an even smaller number is likely to 
reach the clinic in the form of approved diagnostic tests. 
“One of the obstacles is that the FDA doesn’t have clearly delineated pathways 
for biomarker validation, to say nothing of drug-biomarker combinations. They’re trying 
to figure it out as they go. It’s not yet clear what they should be having drug companies 
do in this regard,” Nass says. 
That’s why, she says, the Institute of Medicine report recommends that federal 
agencies, such as the National Institutes of Health, the Centers for Medicare and 
Medicaid Services, and the FDA work with academia, the drug and diagnostics 
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industries, and health insurers to create guidelines for biomarker development, validation 
and use. 
Such a set of guidelines may not become available in the near future. But some 
patients like Patricia Spears are doing fine despite the lack of biomarker-driven decision 
making during treatment. 
Spears is now cancer-free. Her breast cancer never returned after her 
chemotherapy. While Spears was undergoing treatment, her mother was diagnosed with 
breast cancer. That prompted Spears to undergo a bilateral mastectomy a month after her 
treatment ended.  
“My doctors had spotted a pre-cancer in my other breast, and I really didn’t want 
to get diagnosed again,” she says.  
Spears now conducts support groups in Raleigh for women with breast cancer. 
“Some of these new prognostic and predictive tests may be imperfect, but they have 
made a difference. It eases the minds of patients when they know their risk of 
recurrence,” she says. “Knowing whether a patient might respond to chemo makes a huge 
difference.”  
 
 
 
 
 
  
 
 
 
CHAPTER III 
MICROARRAYS AND INFECTIOUS DISEASES 
Editor’s Note: This series of feature stories consists of three articles on the role of 
diagnosis in modern medicine. Traditional and modern methods of diagnosis affect 
treatment choices for patients and have a big impact on health care delivery and costs. 
The first story explains the diagnostic challenges to tailoring cancer treatment to 
patients’ genetic makeup. The second story discusses the role of cutting-edge diagnosis in 
treating infectious diseases, and the third explores the controversy surrounding the 
diagnosis of fibromyalgia. Together, the stories represent three facets of diagnosis – the 
challenges, the promise and the conflicts surrounding this essential part of medical 
practice. This is the second of three stories. 
In December 2005, Dr. Bruce Patterson, director of virology at Stanford Medical 
Center in Palo Alto, Calif., admitted a 28-year-old woman to the hospital for an open 
lung biopsy – a surgical procedure to obtain a piece of lung tissue with the aim of 
arriving at a diagnosis.  
Weeks earlier, the woman had seen her primary care physician at Stanford for 
fever, sore throat, shortness of breath and cough that persisted for 10 days – classic 
symptoms of a respiratory tract infection. Her physician suspected a bacterial infection
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 and prescribed antibiotics. Despite taking antibiotics for three days, the woman’s 
symptoms rapidly worsened. She developed a high fever and had difficulty breathing.  
On the fourth day, she was rushed to the emergency department. X-rays and CT 
scans of her chest showed fluid accumulating in her lungs. To relieve her symptoms 
while waiting to determine the cause of the infection, the woman’s doctors gave her 
antibiotics—ceftriaxone and doxycyclin—followed by the antiviral medication Tamiflu, 
the antifungal drug amphotericin, and steroids. The woman’s symptoms persisted. In 
addition, diagnostic tests for common disease-causing bacteria, fungi and viruses 
revealed no infectious agents in her blood, sputum or lung fluid. That’s when Patterson 
decided to perform a lung biopsy.  
The biopsy shed no light on the cause of the condition. 
As the mystery deepened, Patterson sent samples of bronchial fluids from the 
woman’s breathing tube to the lab of molecular biologist Joseph DeRisi at the University 
of California, San Francisco’s Mission Bay campus. 
The lab, now called the Center for Virus Discovery and Diagnosis of Emerging 
Infections, is a collaborative effort between DeRisi and Dr. Charles Chiu, a UCSF 
infectious diseases specialist. Scientists at the lab combine modern methods of DNA 
analysis with computer algorithms to help doctors discover previously unknown human 
viruses. The discovery of these viruses, which sometimes cause emerging infections, 
hinges on a technology called microarrays.  
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In 2003, DeRisi successfully used microarrays to confirm the identity of a then 
novel coronavirus that had killed more than 50 people in Southeast Asia and sickened 
more than a thousand others. The virus led to the much-publicized SARS epidemic. That 
initial success with microarrays led the former director of the Centers for Disease Control 
and Prevention, Dr. Julie Gerberding, to call microarrays “the absolute state-of-the-art 
probe for viral genes.” 
A virus microarray is a glass slide onto which scientists have spotted thousands of 
snippets of known viral DNA sequences. To determine the cause of an infection, 
scientists take genetic material from patients’ tissues or body fluids and pass them on a 
virus microarray. If the microarray picks up a previously unknown virus that has a 
genetic similarity to a known virus, scientists can isolate the suspect virus and try to link 
it to the patient’s symptoms. 
Patterson, the Stanford virologist who was treating the woman with the 
mysterious ailment, was aware of DeRisi’s work with microarrays. He turned to DeRisi 
in the hope of getting an answer. DeRisi and Chiu had never met the woman, but by 
passing her lung fluid on their microarray, they found what they thought to be the 
explanation for the woman’s illness. 
 “There was a clear signature for one virus in the woman’s bronchial aspirate, and 
it happened to be human parainfluenza virus Type 4,” Chiu says.  
That discovery was not groundbreaking because scientists were aware of the 
virus. But the scientists were surprised to find parainfluenza Type 4 because it was not 
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known to cause anything more severe than a common cold in healthy individuals. 
Parainfluenza Type 4 was not one of the usual suspects for a severe upper respiratory 
tract infection.  
Follow-up tests at UCSF detected antibodies to the virus in the woman’s blood. 
Now that doctors knew what to look for, they could see portions of the virus in her lung 
tissue. Other tests failed to identify any other bacterial or fungal pathogens that could 
have explained the woman’s symptoms.  
Later Chiu would document the case as the first instance of parainfluenza Type 4 
virus causing severe bronchiolitis accompanied by pneumonia in a previously healthy 
patient. In October 2006, he published his findings in the journal Clinical Infectious 
Diseases. 
The woman improved after 26 days of care in the hospital that included some time 
on a ventilator.  
Had the results of the microarray analysis been available weeks earlier, doctors 
might have spared the patient the slew of medications, diagnostic tests and lung biopsy, 
Chiu says. 
“Open lung biopsy is a high risk procedure that carries a mortality rate of about 
five percent. The woman needed the procedure because her doctors were unable to make 
a diagnosis using any of the existing diagnostic tests on her body fluids,” says Chiu.  
The study of emerging viral infections helps doctors discover previously unknown 
viruses that cause illness and helps doctors identify well known viruses—like 
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parainfluenza Type 4—responsible for unusual diseases. Researchers have implicated 
viruses in conditions that were not believed to have a viral cause for many years, such as 
meningitis, encephalitis and even certain kinds of cancer like liver cancer, cervical cancer 
and B cell lymphomas. Novel or not, emerging viral infections have taken tremendous 
tolls on public health in the past. These emerging infections include Ebola virus, Marburg 
virus, Severe Acute Respiratory Syndrome (SARS) virus and the avian flu virus. 
 “You cannot think rationally about either vaccine development or antiviral drug 
development without a knowledge of the complement of viruses that are involved in a 
given condition or outbreak,” says Don Ganem, a UCSF microbiologist, who published 
in 1996 the first electron micrographs of the virus causing Kaposi’s sarcoma in HIV-
infected gay men. 
Traditionally, novel viral pathogens are discovered by growing the viruses in host 
cells in laboratory dishes or by analyzing the viruses in patient samples. Researchers use 
molecular methods such as direct fluorescence antibody staining (DFA), in which a 
fluorescent antibody against a known virus is used to detect the presence of the virus in 
patients’ samples, and polymerase chain reaction (PCR), in which scientists probe the 
DNA of patients’ samples for the presence of a small set of known viral gene sequences.  
Those methods have pitfalls. Many viruses cannot be cultured easily, and those 
that can be cultured take weeks to reproduce and provide enough material for analysis. 
Scientists do not always know the type of host cell that can support the laboratory culture 
of a given virus.  
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Both DFA and PCR depend on the use of specific tools, such as antibodies and 
DNA fragments, to look for known viruses. Those tools often fail to detect a novel virus 
that’s sufficiently different from the viruses for which the tools were developed. In 
addition, the traditional methods are time-consuming and expensive, making them 
undesirable for use when hundreds of patient samples are involved.  
“There is a real need for broad spectrum tests to capture the diversity of viral 
pathogens. There are only three or four different types of diagnostic tests, and they’re not 
sufficient,” Chiu says. 
That’s where DeRisi’s microarray technology enters the picture. “The lesson we 
learned during the SARS outbreak is that we are in a new era of molecular diagnostics. 
Instead of spending months to years looking for viral pathogens, one could use 
microarrays to identify and to sequence viruses associated with disease in literally matters 
of days,” DeRisi says. 
Microarray technology allows scientists to detect in patients’ samples “every virus 
that’s ever been discovered and more,” DeRisi says. His microarray chip is a 1-by-3 inch 
glass slide spotted with more than 20,000 tidbits of nucleic acid bar codes for all known 
viruses. That’s about 2,000 different viruses.  
In a matter of hours, genetic material from a patient’s sample is prepared in the 
lab. Small fluorescent dye molecules are attached to the patient’s genetic material which 
is then passed on the microarray chip. The suspect genetic material is incubated with the 
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chip in an oven for several hours during which time it binds to the viral bar code(s) with 
which it has genetic similarity. The chip is then washed.  
If the suspect genetic material did not bind to any viral bar codes, it gets washed 
away. But if the suspect genetic material matches one or more of the codes, it remains on 
the chip along with the attached fluorescent dye. The chip is then passed through a 
scanner that captures the fluorescence. Computer software translates the fluorescence into 
a specific nucleic acid sequence, a road map that helps confirm the identity of the 
underlying virus. Using the microarray, about 400 patient samples can be analyzed within 
24 hours, a rate at least 10 times faster than that of traditional diagnostic methods for 
viruses. 
To date, DeRisi has used virus microarrays to detect a mouse retrovirus 
implicated in prostate cancer in men with a specific genetic defect, to detect a livestock 
virus that was causing a wasting avian flu in parrots, macaws and cockatiels, and to 
detect a novel human virus that caused intestinal disease. 
“An important caveat to this technology is that if there is a completely new 
virus—one that has no relationship to any known family of viruses—our chip has no 
capability of detecting it,” DeRisi says. The likelihood of running into just such a virus—
the only one of its kind—is impossible to calculate because scientists don’t know 
precisely what percent of human viral pathogens have been charted or how fast viruses 
evolve, he adds. 
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For using the chip commercially and for meeting insurers’ payment guidelines, 
DeRisi would need endorsement from the federal government. To get approval from the 
Food and Drug Administration for the use of his microarray technology for the detection 
of viral pathogens in the clinic, DeRisi would need to demonstrate how sensitive and 
specific his arrays are.  
Sensitivity is a measure of the minimum number of viral particles needed for the 
test to detect the virus in a patient’s sample. Specificity is a measure of the frequency 
with which the test correctly identifies the virus that it is designed to pick up. Both those 
measures apply to diagnostic tests that look for specific targets, such as tests for HIV. But 
DeRisi’s microarray device looks for unknown targets. That means it’s unlikely that he 
would be able to provide the kind of sensitivity and specificity data that FDA regulatory 
authorities require for approval. 
“When you have multiple viruses involved, there’s no practical way to do a 
positive control for the test of every single virus on earth. It’s infeasible,” DeRisi says.  
That’s why DeRisi and Chiu want to make the microarray tool available at their 
new center to doctors everywhere. They have teamed up with a UCSF lab certified by the 
Centers for Medicare and Medicaid Services to carry out such diagnostic tests. The 
certification, called Clinical Laboratory Improvements Amendment, or CLIA, accredits 
the laboratory where tests, such as DeRisi’s microarray test, may be carried out on 
patients’ samples without getting FDA approval.  
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DeRisi and Chiu are conducting a research study of patients with undiagnosed 
conditions of suspected viral cause so they can have the microarray test validated for viral 
discovery in their CLIA-certified lab at UCSF. That would allow them to report their 
findings routinely to clinicians who could use the information to tailor treatment. At this 
time, all the analyses carried out at the center are for basic research only. The center is 
funded by Abbott Diagnostics, a division of the pharmaceutical giant Abbott Labs. 
DeRisi says he hopes the center will be ready to receive patient samples for 
clinical diagnosis before the end of the year. Chiu adds that FDA approval for such a 
microarray-based test is not in sight for at least the next five years. 
DeRisi says the cost of getting a diagnosis at a facility such as the UCSF center 
would be no more than that of single FDA-approved diagnostic test kits that doctors can 
now purchase. Such tests cost between $200 and $300 a kit. Further, a broad-spectrum, 
microarray-based test would screen for many more viruses than any one FDA-approved 
test. 
 
 
 
 
 
 
 
 
  
 
 
 
CHAPTER IV 
 DIAGNOSIS IN CONTROVERSIAL DISORDERS 
Editor’s Note: This series of feature stories consists of three articles on the role of 
diagnosis in modern medicine. Traditional and modern methods of diagnosis affect 
treatment choices for patients and have a big impact on health care delivery and costs. 
The first story explains the diagnostic challenges to tailoring cancer treatment to 
patients’ genetic makeup. The second story discusses the role of cutting-edge diagnosis in 
treating infectious diseases, and the third explores the controversy surrounding the 
diagnosis of fibromyalgia. Together, the stories represent three facets of diagnosis – the 
challenges, the promise and the conflicts surrounding this essential part of medical 
practice. This is the third of three stories. 
Two years ago, 25-year-old Kerry Brewer, a native of Cary, N.C., was a different 
woman. A track-and-field athlete, Brewer took pride in her body’s ability to morph into a 
moving machine. Today, she is thin, gaunt and wiry, the veins on her limbs visibly 
crisscrossing under the skin.  
Brewer’s life revolves around visits to the doctor. In the past two years, Brewer 
has visited more than 30 doctors in search of a name for an ailment whose symptoms 
have ebbed and surged. Her condition remains nameless, but Brewer is convinced it’s 
only a matter of time before she finds a diagnosis. 
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Brewer’s troubles began in the summer of 2006 during a trip to Thailand where 
she taught English to Thai orphans. While at the orphanage, Brewer came down with a 
fever, accompanied by a number of purple spots on her thigh. Antibiotics took care of the 
spots and the fever, which disappeared after a few days. But a rash of symptoms came 
back to haunt her repeatedly, like a returning ghost.  
For the next two years, Brewer suffered bouts of fatigue, fogginess and 
widespread pain of mysterious origin – a combination of nebulous symptoms that defied 
diagnosis and failed to reveal an underlying pathology despite visits to dozens of doctors. 
The symptoms upended Brewer’s life. She declined to enroll in a graduate program in 
Southeast Asian studies at the University of Michigan. Instead, she spent more than six 
months at home trying to nurse herself to health. She now attends graduate school in 
public health at the University of North Carolina at Chapel Hill. 
For 15 years before her trip to Thailand, Brewer had been a star athlete in cross-
country, track and soccer. As a senior at Cary High School, she was captain of the school 
teams for all three sports, was elected the school’s best female athlete in 2002, and was 
voted the most valuable person on her school’s cross-country, track and soccer teams the 
same year. As an undergraduate at the University of North Carolina at Chapel Hill, 
Brewer joined the track team, won five Atlantic Coast Conference championships for 
track events and ran in several national championship meets.  In the fall of 2007, five 
years after graduating from college, Brewer could barely get up from bed, let alone run. 
When she returned from Thailand in September 2006, Brewer visited her primary 
care physician, Dr. James Womble in Cary, N.C., who ordered a number of diagnostic 
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tests, looking for viral and bacterial infections. When the tests revealed nothing, Womble 
sent Brewer to an infectious diseases clinic in Raleigh, N.C., where a specialist ran a 
different battery of tests for rare, tropical infections, such as yellow fever, dengue, 
Japanese encephalitis, shingles, scabies and Whipple’s disease. “The problem with both 
of those appointments was that I appeared to be very sick, and I felt awful. But when they 
would examine me, there wasn’t anything wrong, other than the fact that I was saying I 
felt sick,” Brewer says. 
In the following months, Brewer was tested for an array of problems – nutritional 
deficiencies, allergies, gastrointestinal afflictions, muscular inflammation, ear, nose and 
throat infections and neurological disorders. Pinprick tests for food and environmental 
allergies drew blanks. Balance tests for equilibrium hit dead ends. Endoscopy of her 
swallowing tube and stomach showed nothing amiss. Magnetic resonance imaging scans 
that mapped brain activity picked up nothing of significance. The mystery of the cause of 
her illness lingered while her quest for a solution intensified.  
Brewer is not alone in her plight. Countless patients have grappled with 
symptoms that defy diagnosis. No definitive statistics exist on the number of patients 
seeking a diagnosis for mystery illnesses, but a study by the National Institutes of 
Health’s Genetic and Rare Disease Information Center, or GARD, found that 6.6 percent 
of inquiries to the center between 2005 and 2008 were related to undiagnosed conditions. 
Further, a 2002 GARD study found that about 50 percent of patients seeking a diagnosis 
got one in less than a year; about 30 percent got a diagnosis between one and five years; 
and 15 percent did not receive a diagnosis for at least five years. Furthermore, getting a 
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diagnosis does not mean that a patient’s problem has been correctly identified. The 
diagnosis could be wrong. 
To address the needs of such patients, the National Institutes of Health in 
Bethesda, Md., opened in May 2008 a center that brings together 25 experts from 
different medical disciplines under the aegis of the Undiagnosed Diseases Program. With 
an annual funding of $280,000, program administrators say they want to help patients 
find diagnoses and treatments for rare conditions that the medical community has given 
up on. They also want to develop new diagnostic algorithms. To be admitted to the 
program, a patient must be nominated by a physician willing to make a convincing case 
for the patient’s need for a diagnosis. 
Marianne Genetti, president of the Florida-based nonprofit In Need of Diagnosis, 
says the Undiagnosed Diseases Program is a last-ditch recourse for many people who 
have almost lost hope. “One of things we want to do is to give these people a voice, an 
identity. ‘Undiagnosed’ is a diagnosis. We also want to bring about changes in the 
medical profession to make it easier not just for those people with rare disorders to get a 
diagnosis but for everybody to get diagnosed,” Genetti says. Genetti, 71, has grappled 
with a nameless condition for more than 50 years, one characterized by fatigue, diffuse 
pain and a sporadic inability to move the muscles of her legs. “If there was a fire in my 
house, I could not get up from the couch to leave. I’d go limp,” she says. 
Diagnosis has eluded Genetti despite multiple visits to many specialists at the 
Mayo Clinic in Jacksonville, Fla. Along the way, however, doctors have given her 
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condition labels like “fibromyalgia,” “chronic fatigue syndrome” and “chemical 
sensitivity.” 
Although they failed to provide a diagnosis, Brewer’s physicians suggested that 
she might have chronic fatigue syndrome or fibromyalgia, conditions whose existence is 
hotly debated because of uncertainty about the underlying pathologies.  
Fibromyalgia patients suffer widespread pain, fogginess and fatigue, among other 
symptoms. The disease affects about 10 million Americans, as estimated by doctors 
treating the disease and by advocacy groups supporting patients. Symptoms of 
fibromyalgia do not respond to traditional painkillers, and patients generally do not get 
better with time. The Food and Drug Administration has approved Pfizer’s drug Lyrica 
and Eli Lilly’s drug Cymbalta for the treatment of fibromyalgia.  
Dr. Dan Clauw, a professor of medicine at the University of Michigan, has 
consulted about fibromyalgia for Pfizer and for other drug companies. He says the 
clinical criteria for diagnosing fibromyalgia are not clear-cut. In 1990, the American 
College of Rheumatology put forth criteria for labeling patients with fibromyalgia. These 
criteria were originally intended to target individuals for research studies of fibromyalgia 
and not as clinical diagnostic criteria. These criteria include a history of widespread pain 
for at least three months and pain in 11 of 18 body spots. Despite the limited purpose of 
the diagnostic markers, many doctors have been using the criteria to establish a diagnosis.  
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“These people have the symptoms that they say they have. You can go back in the 
medical literature for millennia and find people that have the exact same symptoms,” 
Clauw says.  
But several physicians refute the existence of the disease, suggesting that drug 
companies and doctors use the diagnosis of fibromyalgia to medically treat a condition 
that might be better managed by psychotherapy or by cognitive behavioral therapy. In his 
book Worried Sick, Dr. Nortin Hadler, a rheumatologist and expert on musculoskeletal 
disorders at the University of North Carolina at Chapel Hill, argues that diagnosing 
patients with fibromyalgia might worsen their condition. He says the diagnosis 
sometimes cements patients’ mistaken belief that their perception of pain is an indication 
of an underlying pathology, and that assumption can lead to unwarranted treatment. 
“[The patients’] narrative is laced with the clinical heuristics they have learned, which 
they can recite with objectivity that approaches the dispassionate,” he writes. 
Clauw disagrees. “There have been different studies that have looked at what 
happens after you give someone the diagnosis of fibromyalgia, and they’ve all shown that 
[the diagnosis] decreases the health care utilization because people stop going to all these 
subspecialists and getting all these diagnostic tests to find out what’s wrong with them,” 
he says.  
Dr. Frederick Wolfe, director of the National Databank for Rheumatic Diseases, 
was among the first physicians to put forth the diagnostic criteria for fibromyalgia. Wolfe 
now concedes that the existence of the disease is debatable, arguing that some doctors 
interpreted painful spots—called tender points—as a diagnostic sign for fibromyalgia. He 
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says the tender points might be the result of stress. Further, he says, physicians vary 
greatly in their ability to detect tender points, rendering the diagnostic criterion shaky. 
Clauw says stress and depression may accompany fibromyalgia in about 40 
percent of patients, but they are unlikely to be the causes of the symptoms. 
“Psychotherapy might help a very small subset of fibromyalgia patients in whom the 
symptoms are driven by psychological and emotional factors, but there are tons of 
fibromyalgia patients who are psychologically normal. There’s a strong underlying 
neurobiological basis to pain sensitivity, and that seems to be why these people have their 
symptoms,” he says.  
Wolfe says the disorder is a specific kind of misery. “This isn’t just ordinary 
misery. It’s an awful lot of misery. In most instances, I don’t agree that the diagnosis of 
fibromyalgia represents an attempt to medicalize misery,” Wolfe says. But he agrees that 
using medication to treat something that might not be treatable can worsen the patient’s 
condition and perpetuate the disorder, a notion some scientists have termed 
“medicalization of psychosocial problems.”  
Many fibromyalgia patients receive drugs that produce more side effects than 
relief. “The rule in medicine is to do as little as possible and as much as is necessary. 
Fibromyalgia as a concept has not been useful to society,” he adds. Wolfe suggests that 
the symptoms that fibromyalgia patients suffer are real, but labeling those symptoms as a 
disorder with the goal of treating the disorder with medication is debatable. 
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Clauw considers that viewpoint escapist. “There are a lot of clinicians who are 
uncomfortable with fibromyalgia patients because we are always uncomfortable when we 
can’t make people better or when we don’t understand what’s going on in their bodies. 
They’re transferring their discomfort in trying to blame the patient. These people are 
really debilitated. They’re not making it up,” he says. 
Wolfe says physicians who believe in fibromyalgia as a real disease cite specific 
abnormalities in the central nervous system as the underpinning of the disorder. “And 
that’s where one has a problem because there isn’t any good evidence of causality,” he 
says. 
Clauw suggests that such a claim is unfounded. “These suppositions fall apart 
when you look at the scientific data. [The detractors] rely on their eminence, not on the 
evidence. Saying that this is the medical [treatment] of misery or the pharmaceutical 
companies mongering pills is overly simplistic and downright wrong,” he says. 
Brewer remembers a turning point in the course of her illness as an unpleasant 
meeting with her physician Womble. She recalled, “He brought me into his office, and 
said, ‘Kerry, I need to be honest with you. There’s nothing wrong with you, and I suggest 
that you see a psychiatrist. It seems like mostly you’ve just worked yourself up into such 
a tizzy about this whole thing. It’s just psychiatric.’”  
The pronouncement took Brewer by surprise. “I just couldn’t believe that this 
person who had known me for years was accusing me of creating a physical disorder 
through my mind. He was saying I was causing it myself,” she says. 
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Brewer says Womble suggested that she was imagining the illness to escape from 
her possibly unhappy life situation or to malinger. “Why would I want to do that? I 
worked very hard to qualify for the world championship. I had a full scholarship to start 
grad school. Why wouldn’t I want to do those things? Why would I create an illness to 
back out of that? My family was upset with him. We all stopped going to see him,” she 
adds. 
Womble explains: “Often, the worry and anxiety about not having a diagnosis can 
produce physical symptoms. Those can be confusing and can make it more difficult to 
make a diagnosis sometimes.” He adds that once a physician has ruled out an organic 
cause for the symptoms, it’s reasonable to reassure the patient “that they don’t have 
anything of a serious nature.” 
In October 2007, Brewer found Dr. Alan Spanos, a pain specialist at Blue Ridge 
Clinical Associates in Chapel Hill, N.C. “He is exactly what I had been looking for, 
someone who’s unwilling to give up,” Brewer says. 
Spanos, a British doctor who has lived in the U.S. since 1979, says an infection 
that cannot be diagnosed using laboratory tests could be the cause of Brewer’s condition. 
“My official diagnosis was to describe the condition and be open-minded about what it 
might turn out to be,” Spanos says. “We have examples of infectious diseases which sit 
around for a long time, making us all scratch our heads until we finally are able to 
virtually see the germ under the microscope.” 
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Spanos suggested that Brewer take a mix of drugs, some in series, others in 
concert: beta-blockers for her increased heart-beat rate; strong anti-emetics—commonly 
used by cancer patients—to suppress her nausea; antibiotics to quell any infectious agents 
lurking in her body; pain medication for her aching muscles; medication commonly given 
to geriatric patients to retain nutrients in the blood longer than usual; and energy boosters 
prescribed for patients of narcolepsy and attention deficit hyperactivity disorder. The 
regimen worked for a while before Brewer’s health took another nosedive. 
Brewer’s symptoms recurred unabated throughout the winter of 2007, and as a 
last-ditch effort, Spanos suggested that she take an antibiotic cocktail daily. The drugs—
doxycyclin and minocycline—alleviated most of her symptoms and kept her functional. 
“There’s no real reason that I’m taking it other than the fact that it works,” Brewer says. 
Spanos says he was outraged at Womble’s suggestion that Brewer see a 
psychiatrist for her troubles. “In contemporary American medicine, there’s an unfortunate 
tendency to say that it doesn’t matter what the patient is telling me, it doesn’t matter how 
they look, it doesn’t matter what they find on examination – if the tests are all negative, 
then they’re not really ill. This is obvious baloney and would be treated as baloney in 
almost every other country in the world,” he says. 
“Doctors would much rather make a diagnosis—even the demeaning and 
potentially false one of a psychiatric condition—than admit to the patient and to 
themselves that this is an unusual illness. We don’t know what it is,” Spanos says. “There 
are quite a few folks out there with illnesses which are not in our textbooks. Not only are 
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they not in our textbooks, but we don’t even know what chapter of the textbook they 
should go in.” 
Brewer continues to search for a definitive diagnosis amid the welter of names 
that hover around her condition: fibromyalgia, chronic fatigue syndrome, a mysterious 
infection and metabolic deficiency. Out of desperation, she has accepted that her quest to 
find a name and cause of her condition might continue indefinitely.  
On the other hand, she keeps looking for answers. “I still have hope that there is 
this simple explanation and this simple drug that I could take that will make it all better. I 
hope that a lot less than I used to, but I still hold on to that hope,” she says. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
CHAPTER V 
 FUTURE PERSPECTIVES 
The three stories in this thesis provide insights into the role of diagnosis in 
personalized cancer treatment, in the treatment of infectious diseases and in the plight of 
patients suffering from controversial disorders. But they also raise a number of questions 
for future exploration. 
 Molecular diagnosis has just begun to reshape doctors’ approach to cancer 
therapy, but there are several roadblocks along the way, some of which the story on 
cancer biomarkers addresses. Other concerns not broached in the story could form the 
bases for future stories on personalized cancer treatment. One concern relates to the 
challenges to translating basic research for biomarker discovery, which happens in 
laboratory settings, into clinical trials for biomarker validation, which happens in hospital 
settings. Basic researchers working to find biomarkers for cancer are sometimes unaware 
of how patients’ samples were collected, stored and compared in clinical settings. In the 
past, that gap in knowledge has led to unwarranted assumptions and, therefore, unreliable 
biomarkers. Another concern relates to the Herculean task of determining the uniqueness 
of individuals’ cancer. Such an endeavor would ideally involve tens of thousands of 
patients and millions of dollars. Attempts to personalize cancer therapy are doomed to 
fail without this knowledge, and cancer researchers are now trying to chart the panoply of
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 genetic abnormalities found in certain types of cancer with the goal of determining 
which of those changes could trigger cancer.  
Using microarrays, scientists have made inroads into the discovery of novel 
viruses and of emerging infections, as the second story in the series shows. But it’s hard 
to get approval from the Food and Drug Administration for the use of microarrays in the 
development of clinical diagnostic tests, partly because the FDA is unsure of how to go 
about setting up benchmarks for such approval. One ongoing effort by the FDA—the 
Microarray Quality Control Project—addresses some of those problems and is aimed at 
publishing a set of guidelines later this year for the use of microarrays in diagnostics. 
This is an emerging field of research with many unanswered questions – and a gold mine 
of story ideas for future popular science stories. 
The story on controversial diseases, such as fibromyalgia, highlights the patient’s 
perspective while setting up the debate between the proponents of the biological and 
psychosocial causes of fibromyalgia. Many intriguing research questions relate to such 
conditions, which would lend themselves to popular storytelling: How does the 
processing of pain by the human body make some individuals sensitive to stimuli that are 
not normally painful? Does the interplay between the nervous system and hormones 
produce some of the symptoms associated with chronic pain? Can exercise improve the 
body’s ability to handle stress and reduce pain perception in individuals with 
fibromyalgia? Could some individuals have a genetic predisposition to fibromyalgia? 
Scientists are beginning to answer some of these questions. For others, the answers seem 
obscure.  
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Guidance to reporters covering medical stories 
Medical stories tend to present unique challenges to reporters because of the often 
complex nature of the underlying science and the dense, scholarly language of academic 
medical journals, which regularly serve as source materials for stories. To ensure that 
readers understand the importance, implications, nuances and limitations of medical 
advances, reporters could follow several steps to make their arguments convincing and 
their stories readable. Here, I have listed six simple strategies that could help medical 
journalists make their prose lucid to a lay audience: 
 Metaphors and analogies can help reporters render abstract scientific phenomena 
concrete to the lay reader. Choosing metaphors wisely is no mean feat; a well-
chosen metaphor should help a reader understand a concept and its intricate 
details. Reporters could also ask the scientific expert to come up with literary 
devices and then attribute the usage to the source. 
 Reporters should avoid using jargon in popular stories. Instead, they should 
explain concepts in plain English. 
 Science writers can avoid confusion in their writing by backing into explanations. 
This time-tested strategy in science writing consists of explaining scientific 
concepts before labeling them. 
 One way to make text readable, especially while dealing with complicated subject 
matter, is to use a combination of techniques for spare, straightforward writing: 
using short, declarative sentences; limiting the number of ideas per sentence to 
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one; choosing five-cent words over fancy, ten-dollar alternatives; culling adverbs 
and adjectives; and avoiding passive voice whenever possible. 
  The power of narrative structure in helping readers wrap their minds around 
complex ideas can never be stressed enough. Narrative is probably the journalist’s 
single most important trick in the toolbox. The AB-BC-CD rule in narrative 
writing—picking up on the last word of a preceding sentence or graf to begin a 
new one—helps ensure continuity of expression. Also, transitional phrases can 
ensure that a story’s progression resembles a purposeful flow rather than an 
aimless wander. Such structural formulae act like chicken-wire in a story, helping 
the writer herd all the tangential subplots into a multidimensional story. 
 Finally, reporters should follow the cardinal rule in science writing: Never write 
about what you don’t understand. 
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